Glucocorticoids increase CD4 +CD25 high cell percentage and Foxp3 expression in patients with multiple sclerosis

Acta Neurologica Scandinavica

Volumn 119, Issue 4, 2009, Pages 239-245

  Braitch, M ^b   Harikrishnan, S ^b   Robins, R A ^a   Nichols, C ^c   Fahey, A J ^b   Showe, L ^c   Constantinescu, C S ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b School of Medical and Surgical Sciences   (United Kingdom)

^c WISTAR INSTITUTE   (United States)

Author keywords

CD25; Cytokines; Foxp3; Glucocorticoids; Methylprednisolone; Multiple sclerosis; Regulatory T cells

Indexed keywords

CD3 ANTIGEN; DEXAMETHASONE; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; METHYLPREDNISOLONE; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; GLUCOCORTICOID; IL10 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CD4+ CD25+ T LYMPHOCYTE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; RELAPSE; REMISSION; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE;

ADULT; AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-6; LYMPHOCYTE COUNT; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY;

EID: 61849112650     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2008.01090.x     Document Type: Article

References (31)

1. Sakaguchi S, Sakaguchi N. Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int Rev Immunol 2005 24 : 211 26.
2. Curotto De Lafaille MA, Lafaille JJ. CD4(+) regulatory T cells in autoimmunity and allergy. Curr Opin Immunol 2002 14 : 771 8.
3. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995 155 : 1151 64.
4. Bettelli E, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci USA 2005 102 : 5138 43.
5. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007 13 : 108 16.
6. Kohm AP, Carpentier PA, Anger HA, Miller SD. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol 2002 169 : 4712 6.
7. Chen X, Oppenheim JJ, Winkler-Pickett RT, Ortaldo JR, Howard OM. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol 2006 36 : 2139 49.
8. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004 199 : 971 9.
9. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003 299 : 1033 6.
10. Sutmuller RP, Morgan ME, Netea MG, Grauer O, Adema GJ. Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol 2006 27 : 387 93.
11. Karagiannidis C, Akdis M, Holopainen P et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 2004 114 : 1425 33.
12. Lamas M, Sanz E, Martin-Parras L et al. Glucocorticoid hormones upregulate interleukin 2 receptor alpha gene expression. Cell Immunol 1993 151 : 437 50.
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 33 : 1444 52.
14. Kari L, Loboda A, Nebozhyn M et al. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003 197 : 1477 88.
15. Yagi H, Nomura T, Nakamura K et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 2004 16 : 1643 56.
16. Leussink VI, Jung S, Merschdorf U, Toyka KV, Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol 2001 58 : 91 7.
17. Gayo A, Mozo L, Suarez A, Tunon A, Lahoz C, Gutierrez C. Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse. J Neuroimmunol 1998 85 : 122 30.
18. Chen X, Murakami T, Oppenheim JJ, Howard OM. Differential response of murine CD4+CD25+ and CD4+CD25- T cells to dexamethasone-induced cell death. Eur J Immunol 2004 34 : 859 69.
19. Pillai V, Ortega SB, Wang CK, Karandikar NJ. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 2007 123 : 18 29.
20. Navarro J, Aristimuno C, Sanchez-Ramon S et al. Circulating dendritic cells subsets and regulatory T-cells at multiple sclerosis relapse: differential short-term changes on corticosteroids therapy. J Neuroimmunol 2006 176 : 153 61.
21. Sahid El-Radhi A, Hogg CL, Bungre JK, Bush A, Corrigan CJ. Effect of oral glucocorticoid treatment on serum inflammatory markers in acute asthma. Arch Dis Child 2000 83 : 158 62.
22. Dhawan L, Liu B, Blaxall BC, Taubman MB. A novel role for the glucocorticoid receptor in the regulation of monocyte chemoattractant protein-1 mRNA stability. J Biol Chem 2007 282 : 10146 52.
23. Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 2005 11 : 425 32.
24. Wust S, Van Den Brandt J, Tischner D et al. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J Immunol 2008 180 : 8434 43.
25. Tsutsui S, Vergote D, Shariat N, Warren K, Ferguson SS, Power C. Glucocorticoids regulate innate immunity in a model of multiple sclerosis: reciprocal interactions between the A1 adenosine receptor and beta-arrestin-1 in monocytoid cells. FASEB J 2008 22 : 786 96.
26. Moreira MA, Tilbery CP, Monteiro LP, Teixeira MM, Teixeira AL. Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis. Acta Neurol Scand 2006 114 : 109 13.
27. Elovaara I, Kuusisto H, Paalavuo R et al. Effect of high-dose methylprednisolone treatment on CCR5 expression on blood cells in MS exacerbation. Acta Neurol Scand 2006 113 : 163 6.
28. De Andres C, Aristimuno C, De Las Heras V et al. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J Neuroimmunol 2007 182 : 204 11.
29. Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007 4 : 647 53.
30. Fahey AJ, Robins RA, Kindle KB, Heery DM, Constantinescu CS. Effects of glucocorticoids on STAT4 activation in human T cells are stimulus-dependent. J Leukoc Biol 2006 80 : 133 44.
31. Cohen JA, Calabresi PA, Chakraborty S et al. Avonex Combination Trial in relapsing-remitting MS: rationale, design and baseline data. Mult Scler 2008 14 : 370 82.